Oct 18, 2021 7:30am EDT Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel
Sep 22, 2021 6:00pm EDT Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine
Sep 20, 2021 7:00am EDT Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial
Sep 13, 2021 4:30pm EDT Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021
Sep 08, 2021 7:00am EDT Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
Aug 24, 2021 7:00am EDT Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
Aug 11, 2021 7:00am EDT Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update
Jun 04, 2021 9:05am EDT Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting